Current advances in research and clinical applications of PLGA-based nanotechnology

References

• Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer120(12), 2527–2537 (2007).
   PubMed Web of Science ®Google Scholar
• Whitesides GM. Nanoscience, nanotechnology, and chemistry. Small1(2), 172–179 (2005).
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J.19(3), 311–330 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson M. Nanomedicine – a tremendous research opportunity for analytical chemists. Analyst129, 671 (2004).
   PubMedGoogle Scholar
• Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today8(24), 1112–1120 (2003).
   PubMed Web of Science ®Google Scholar
• Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler. Thromb. Vasc. Biol.26(3), 435–441 (2006).
   PubMedGoogle Scholar
• Lipinski MJ, Fuster V, Fisher EA, Fayad ZA. Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat. Clin. Pract. Cardiovasc. Med.1(1), 48–55 (2004).
   PubMedGoogle Scholar
• Guccione S, Li KC, Bednarski MD. Vascular-targeted nanoparticles for molecular imaging and therapy. Methods Enzymol.386, 219–236 (2004).
   PubMedGoogle Scholar
• Yang X. Nano- and microparticle-based imaging of cardiovascular interventions: overview. Radiology243(2), 340–347 (2007).
   PubMed Web of Science ®Google Scholar
• Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging25(4), 667–680 (2007).
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev.53(2), 283–318 (2001).
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J.9(2), E128–E147 (2007).
   PubMed Web of Science ®Google Scholar
• Patel DN, Bailey SR. Nanotechnology in cardiovascular medicine. Catheter Cardiovasc. Interv.69(5), 643–654 (2007).
   PubMed Web of Science ®Google Scholar
• Hawker CJ, Wooley KL. The convergence of synthetic organic and polymer chemistries. Science309(5738), 1200–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev.55(3), 329–347 (2003).
   PubMed Web of Science ®Google Scholar
• Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials21(23), 2475–2490 (2000).
   PubMed Web of Science ®Google Scholar
• Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch. Intern. Med.165(7), 725–730 (2005).
   PubMed Web of Science ®Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed.17(3), 247–289 (2006).
   PubMed Web of Science ®Google Scholar
• Zambaux MF, Bonneaux F, Gref R et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control Release50(1–3), 31–40 (1998).
   PubMed Web of Science ®Google Scholar
• Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release79(1–3), 123–135 (2002).
   PubMed Web of Science ®Google Scholar
• Avgoustakis K, Beletsi A, Panagi Z et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm.259(1–2), 115–127 (2003).
   PubMed Web of Science ®Google Scholar
• Hyon SH. Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med. J.41(6), 720–734 (2000).
   PubMed Web of Science ®Google Scholar
• Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J.16(10), 1217–1226 (2002).
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control Release82(1), 105–114 (2002).
   PubMed Web of Science ®Google Scholar
• Cheng FY, Wang SP, Su CH et al. Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials29(13), 2104–2112 (2008).
   PubMed Web of Science ®Google Scholar
• Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials17(2), 93–102 (1996).
   PubMed Web of Science ®Google Scholar
• Kitchell JP, Wise DL. Poly(lactic/glycolic acid) biodegradable drug-polymer matrix systems. Methods Enzymol.112, 436–448 (1985).
   PubMed Web of Science ®Google Scholar
• Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev.28(1), 5–24 (1997).
   PubMed Web of Science ®Google Scholar
• Saxena V, Sadoqi M, Shao J. Polymeric nanoparticulate delivery system for indocyanine green: biodistribution in healthy mice. Int. J. Pharm.308(1–2), 200–204 (2006).
   PubMed Web of Science ®Google Scholar
• Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv.1(4), 321–333 (2004).
   PubMedGoogle Scholar
• van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol. Pharm.5(4), 516–526 (2008).
   PubMed Web of Science ®Google Scholar
• Igartua M, Hernandez RM, Rosas JE, Patarroyo ME, Pedraz JL. γ-irradiation effects on biopharmaceutical properties of PLGA microspheres loaded with SPf66 synthetic vaccine. Eur. J. Pharm. Biopharm.69(2), 519–526 (2008).
   PubMed Web of Science ®Google Scholar
• Shearer H, Ellis MJ, Perera SP, Chaudhuri JB. Effects of common sterilization methods on the structure and properties of poly(D,L- lactic-co-glycolic acid) scaffolds. Tissue Eng.12(10), 2717–2727 (2006).
   PubMedGoogle Scholar
• Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev. Ind. Pharm.24(8), 703–727 (1998).
   PubMed Web of Science ®Google Scholar
• Prasad S, Cody V, Hanlon D et al. Biopolymer nanoparticles as antigen delivery vehicles for immunotherapy of head and neck squamous cell carcinoma (HNSCC). Clin. Otolaryngol.33(3), 304 (2008).
   Google Scholar
• Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm. Res.21(2), 354–364 (2004).
   PubMed Web of Science ®Google Scholar
• Panyam J, Dali MM, Sahoo SK et al. Polymer degradation and in vitro release of a model protein from poly(,-lactide-co-glycolide) nano- and microparticles. J. Control Release92(1–2), 173–187 (2003).
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(,-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res.20(2), 212–220 (2003).
   PubMed Web of Science ®Google Scholar
• van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res.17(10), 1159–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Vinagradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Del. Rev., 54, 223–233 (2002).
   PubMedGoogle Scholar
• Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ329(7480), 1447–1450 (2004).
   PubMed Web of Science ®Google Scholar
• Vorp DA, Maul T, Nieponice A. Molecular aspects of vascular tissue engineering. Front. Biosci.10, 768–789 (2005).
   PubMed Web of Science ®Google Scholar
• Tu JV, Pashos CL, Naylor CD et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N. Engl. J. Med.336(21), 1500–1505 (1997).
   PubMedGoogle Scholar
• McKee JA, Banik SS, Boyer MJ et al. Human arteries engineered in vitro. EMBO Rep.4(6), 633–638 (2003).
   PubMed Web of Science ®Google Scholar
• Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM. Current status of prosthetic bypass grafts: a review. J. Biomed. Mater. Res. B Appl. Biomater.74(1), 570–581 (2005).
   PubMed Web of Science ®Google Scholar
• Salacinski HJ, Goldner S, Giudiceandrea A et al. The mechanical behavior of vascular grafts: a review. J. Biomater. Appl.15(3), 241–278 (2001).
   PubMed Web of Science ®Google Scholar
• Kakisis JD, Liapis CD, Breuer C, Sumpio BE. Artificial blood vessel: the Holy Grail of peripheral vascular surgery. J. Vasc. Surg.41(2), 349–354 (2005).
   PubMed Web of Science ®Google Scholar
• Hoenig MR, Campbell GR, Rolfe BE, Campbell JH. Tissue-engineered blood vessels: alternative to autologous grafts? Arterioscler. Thromb. Vasc. Biol.25(6), 1128–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Wang X, Lin P, Yao Q, Chen C. Development of small-diameter vascular grafts. World J. Surg.31(4), 682–689 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson RW. Reflections on the pathogenesis of abdominal aortic aneurysms. Cardiovasc. Surg.10(4), 389–394 (2002).
   PubMedGoogle Scholar
• Niklason LE. Techview: medical technology. Replacement arteries made to order. Science286(5444), 1493–1494 (1999).
   PubMed Web of Science ®Google Scholar
• Niklason LE, Gao J, Abbott WM et al. Functional arteries grown in vitro. Science284(5413), 489–493 (1999).
   PubMed Web of Science ®Google Scholar
• Sarkar S, Lee GY, Wong JY, Desai TA. Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials27(27), 4775–4782 (2006).
   PubMed Web of Science ®Google Scholar
• Yang S, Leong KF, Du Z, Chua CK. The design of scaffolds for use in tissue engineering. Part I. Traditional factors. Tissue Eng.7(6), 679–689 (2001).
   PubMedGoogle Scholar
• Hwang CM, Khademhosseini A, Park Y, Sun K, Lee SH. Microfluidic chip-based fabrication of PLGA microfiber scaffolds for tissue engineering. Langmuir24(13), 6845–6851 (2008).
   PubMed Web of Science ®Google Scholar
• Robb BW, Wachi H, Schaub T, Mecham RP, Davis EC. Characterization of an in vitro model of elastic fiber assembly. Mol. Biol. Cell10(11), 3595–3605 (1999).
   PubMedGoogle Scholar
• Lee BH, Nam HY, Kwon T et al. Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol. Dial. Transplant.21(9), 2432–2438 (2006).
   PubMedGoogle Scholar
• Lim HJ, Nam HY, Lee BH, Kim DJ, Ko JY, Park JS. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Biotechnol. Prog.23(3), 693–697 (2007).
   PubMed Web of Science ®Google Scholar
• Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur. J. Vasc. Endovasc. Surg.27(4), 357–362 (2004).
   PubMed Web of Science ®Google Scholar
• Shirota T, He H, Yasui H, Matsuda T. Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing. Tissue Eng.9(1), 127–136 (2003).
   PubMedGoogle Scholar
• Cho SW, Lim SH, Kim IK et al. Small-diameter blood vessels engineered with bone marrow-derived cells. Ann. Surg.241(3), 506–515 (2005).
   PubMed Web of Science ®Google Scholar
• Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation106(10), 1199–1204 (2002).
   PubMed Web of Science ®Google Scholar
• Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm.233(1–2), 51–59 (2002).
   PubMed Web of Science ®Google Scholar
• Iverson N, Plourde N, Chnari E, Nackman GB, Moghe PV. Convergence of nanotechnology and cardiovascular medicine : progress and emerging prospects. BioDrugs22(1), 1–10 (2008).
   PubMedGoogle Scholar
• Cui W, Bei J, Wang S et al. Preparation and evaluation of poly(-lactide-co-glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography. J. Biomed. Mater. Res. B Appl. Biomater.73(1), 171–178 (2005).
   PubMedGoogle Scholar
• Wheatley MA, Forsberg F, Oum K, Ro R, El-Sherif D. Comparison of in vitro and in vivo acoustic response of a novel 50:50 PLGA contrast agent. Ultrasonics44(4), 360–367 (2006).
   PubMed Web of Science ®Google Scholar
• Lathia JD, Leodore L, Wheatley MA. Polymeric contrast agent with targeting potential. Ultrasonics42(1–9), 763–768 (2004).
   PubMed Web of Science ®Google Scholar
• Bauters C, Banos JL, Van Belle E, McFadden EP, Lablanche JM, Bertrand ME. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation97(4), 318–321 (1998).
   PubMed Web of Science ®Google Scholar
• Ganaha F, Kao EY, Wong H et al. Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis. J. Vasc. Interv. Radiol.15(6), 601–608 (2004).
   PubMedGoogle Scholar
• Reimers B, Moussa I, Akiyama T et al. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J. Am. Coll. Cardiol.30(1), 186–192 (1997).
   PubMed Web of Science ®Google Scholar
• Klugherz BD, Jones PL, Cui X et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotechnol.18(11), 1181–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Perlstein I, Connolly JM, Cui X et al. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther.10(17), 1420–1428 (2003).
   PubMed Web of Science ®Google Scholar
• Banai S, Gertz SD, Gavish L et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc. Res.64(1), 165–171 (2004).
   PubMedGoogle Scholar
• Yang Z, Birkenhauer P, Julmy F et al. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J. Control. Release60(2–3), 269–277 (1999).
   PubMed Web of Science ®Google Scholar
• Schwartz SM, deBlois D, O’Brien ER. The intima. Soil for atherosclerosis and restenosis. Circ. Res.77(3), 445–465 (1995).
   PubMed Web of Science ®Google Scholar
• Guzman LA, Labhasetwar V, Song C et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation94(6), 1441–1448 (1996).
   PubMed Web of Science ®Google Scholar
• Suh H, Jeong B, Rathi R, Kim SW. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J. Biomed. Mater. Res.42(2), 331–338 (1998).
   PubMed Web of Science ®Google Scholar
• Zhu W, Masaki T, Bae YH, Rathi R, Cheung AK, Kern SE. Development of a sustained-release system for perivascular delivery of dipyridamole. J. Biomed. Mater. Res. B Appl. Biomater.77(1), 135–143 (2006).
   PubMedGoogle Scholar
• Cleek RL, Rege AA, Denner LA, Eskin SG, Mikos AG. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(-lactic-co-glycolic acid) microparticles. J. Biomed. Mater. Res.35(4), 525–530 (1997).
   PubMed Web of Science ®Google Scholar
• Mei L, Sun H, Jin X et al. Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm. Res.24(5), 955–962 (2007).
   PubMed Web of Science ®Google Scholar
• Westedt U, Kalinowski M, Wittmar M et al. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. J. Control Release119(1), 41–51 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen-Sacks H, Najajreh Y, Tchaikovski V et al. Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther.9(23), 1607–1616 (2002).
   PubMed Web of Science ®Google Scholar
• Kaul S, Cercek B, Rengstrom J et al. Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-κB. J. Am. Coll. Cardiol.35(2), 493–501 (2000).
   PubMed Web of Science ®Google Scholar
• Lavisse S, Paci A, Rouffiac V et al.In vitro echogenicity characterization of poly[lactide-coglycolide] (PLGA) microparticles and preliminary in vivo ultrasound enhancement study for ultrasound contrast agent application. Invest. Radiol.40(8), 536–544 (2005).
   PubMedGoogle Scholar
• Goldberg SN, Walovitch RC, Straub JA, Shore MT, Gazelle GS. Radio-frequency-induced coagulation necrosis in rabbits: immediate detection at US with a synthetic microsphere contrast agent. Radiology213(2), 438–444 (1999).
   PubMedGoogle Scholar
• Forsberg F, Lathia JD, Merton DA et al. Effect of shell type on the in vivo backscatter from polymer-encapsulated microbubbles. Ultrasound Med. Biol.30(10), 1281–1287 (2004).
   PubMedGoogle Scholar
• Mo Y, Lim LY. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J. Control. Release108(2–3), 244–262 (2005).
   PubMed Web of Science ®Google Scholar
• Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release83(2), 273–286 (2002).
   PubMed Web of Science ®Google Scholar
• Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int. J. Pharm.326(1–2), 174–181 (2006).
   PubMed Web of Science ®Google Scholar
• Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm.67(1), 1–8 (2007).
   PubMed Web of Science ®Google Scholar
• Yemisci M, Bozdag S, Cetin M et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery59(6), 1296–1302; discussion 1302–1303 (2006).
   PubMed Web of Science ®Google Scholar
• Pai Kasturi S, Qin H, Thomson KS et al. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J. Control. Release113(3), 261–270 (2006).
   PubMed Web of Science ®Google Scholar
• Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release120(1–2), 18–26 (2007).
   PubMed Web of Science ®Google Scholar
• Benny O, Duvshani-Eshet M, Cargioli T et al. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth. Clin. Cancer Res.11(2 Pt 1), 768–776 (2005).
   PubMed Web of Science ®Google Scholar
• Lagarce F, Garcion E, Faisant N et al. Development and characterization of interleukin-18-loaded biodegradable microspheres. Int. J. Pharm.314(2), 179–188 (2006).
   PubMedGoogle Scholar
• Bharali DJ, Mousa SA, Thanavala Y. Micro- and nanoparticle-based vaccines for hepatitis B. Adv. Exp. Med. Biol.601, 415–421 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J. Pharm. Sci.85(12), 1261–1270 (1996).
   PubMed Web of Science ®Google Scholar
• Mok H, Park TG. Direct plasmid DNA encapsulation within PLGA nanospheres by single oil-in-water emulsion method. Eur. J. Pharm. Biopharm.68(1), 105–111 (2008).
   PubMed Web of Science ®Google Scholar
• Denis-Mize KS, Dupuis M, Singh M et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell. Immunol.225(1), 12–20 (2003).
   PubMed Web of Science ®Google Scholar
• Peyre M, Sesardic D, Merkle HP, Gander B, Johansen P. An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. J. Pharm. Sci.92(5), 957–966 (2003).
   PubMed Web of Science ®Google Scholar
• Smith DJ, Trantolo DJ, King WF et al. Induction of secretory immunity with bioadhesive poly (,-lactide-co-glycolide) microparticles containing Streptococcus sobrinus glucosyltransferase. Oral Microbiol. Immunol.15(2), 124–130 (2000).
   PubMedGoogle Scholar
• Nayak B, Panda AK, Ray P, Ray AR. Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J. Microencapsul.1–12 (2008).
   PubMedGoogle Scholar
• Audran R, Peter K, Dannull J et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine21(11–12), 1250–1255 (2003).
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Allmen EU, Gander B et al. Encapsulation of proteins and peptides into biodegradable poly(,-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine24(11), 1847–1857 (2006).
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E et al. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J. Immunol. Methods287(1–2), 109–124 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials28(5), 869–876 (2007).
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J. Control. Release79(1–3), 29–40 (2002).
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Somayaji V, Ruan D, Samuel J. Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (,-lactic-co-glycolic acid) nanoparticle formulations. J. Pharm. Biomed. Anal.44(4), 914–923 (2007).
   PubMed Web of Science ®Google Scholar
• Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(,-lactic-co-glycolic acid) nanoparticles. J. Biomed. Mater. Res. A, 81(3), 652–662 (2007).
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J. Immunother.30(4), 378–395 (2007).
   PubMed Web of Science ®Google Scholar
• Wischke C, Zimmermann J, Wessinger B et al. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm.365(1-2), 61–68 (2008).
   PubMedGoogle Scholar
• Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine19(15–16), 1940–1950 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target15(10), 701–713 (2007).
   PubMed Web of Science ®Google Scholar
• Garinot M, Fievez V, Pourcelle V et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control Release120(3), 195–204 (2007).
   PubMed Web of Science ®Google Scholar
• Wendorf J, Chesko J, Kazzaz J et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum. Vaccin.4(1), 44–49 (2008).
   PubMed Web of Science ®Google Scholar
• Boehm G, Peyre M, Sesardic D et al. On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm. Res.19(9), 1330–1336 (2002).
   PubMed Web of Science ®Google Scholar
• Spiers ID, Alpar HO, Eyles JE, Bozkir A, Miller J, Williamson ED. Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis. J. Pharm. Pharmacol.51(9), 991–997 (1999).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Spiers ID, Stagg AJ, Jones SM, Alpar HO. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J. Control. Release63(1–2), 191–200 (2000).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Spiers ID, Alpar HO. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine18(28), 3266–3271 (2000).
   PubMed Web of Science ®Google Scholar
• Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol.37(8), 2063–2074 (2007).
   PubMed Web of Science ®Google Scholar
• Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(,-lactide-co-glycolide) and its derivatives. J. Control. Release125(3), 193–209 (2008).
   PubMed Web of Science ®Google Scholar
• Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int. J. Pharm.331(2), 228–232 (2007).
   PubMed Web of Science ®Google Scholar
• Cui FD, Tao AJ, Cun DM, Zhang LQ, Shi K. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci.96(2), 421–427 (2007).
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang SM, Chen PP et al. Controlled release of insulin from PLGA nanoparticles embedded within PVA hydrogels. J. Mater. Sci. Mater. Med.18(11), 2205–2210 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar PS, Ramakrishna S, Saini TR, Diwan PV. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles. Pharmazie61(7), 613–617 (2006).
   PubMed Web of Science ®Google Scholar
• Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release114(2), 242–250 (2006).
   PubMed Web of Science ®Google Scholar
• Basarkar A, Singh J. Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm. Res.26(1), 72–81 (2008).
   PubMedGoogle Scholar
• Tosi G, Costantino L, Rivasi F et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J. Control. Release122(1), 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Klose D, Laprais M, Leroux V et al. Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke. Eur J. Pharm. Sci.37(1), 43–52 (2009).
   PubMedGoogle Scholar
• Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx2(1), 108–119 (2005).
   PubMedGoogle Scholar
• Tamura T, Kita T, Nakagawa T et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope115(11), 2000–2005 (2005).
   PubMed Web of Science ®Google Scholar
• Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y. Treatment of experimental arthritis with poly(D,L-lactic/glycolic acid) nanoparticles encapsulating β methasone sodium phosphate. Ann. Rheum. Dis.64(8), 1132–1136 (2005).
   PubMed Web of Science ®Google Scholar
• Kim WU, Lee WK, Ryoo JW et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum.46(4), 1109–1120 (2002).
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Yamamoto H et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther.299(2), 775–781 (2001).
   PubMed Web of Science ®Google Scholar
• Feng SS, Zeng W, Teng Lim Y et al. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomedicine2(3), 333–344 (2007).
   PubMed Web of Science ®Google Scholar
• Nehilla BJ, Bergkvist M, Popat KC, Desai TA. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles. Int. J. Pharm.348(1–2), 107–114 (2008).
   PubMedGoogle Scholar
• Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl. Biochem. Biotechnol.151(2–3), 565–577 (2008).
   PubMed Web of Science ®Google Scholar